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ABSTRACT 39	
Purpose: Pulmonary antibiotic delivery is recommended as maintenance therapy for cystic 40	
fibrosis (CF) patients who experience chronic infections. However, abnormally thick and sticky 41	
mucus present in the respiratory tract of CF patients impairs mucus penetration and limits the 42	
efficacy of inhaled antibiotics. To overcome the obstacles of pulmonary antibiotic delivery, we 43	
have developed nanocomposite microparticles (nCmP) for the inhalation application of 44	
antibiotics in the form of dry powder aerosols.  45	
Methods: Azithromycin-loaded and rapamycin-loaded polymeric nanoparticles (NP) were 46	
prepared via nanoprecipitation and nCmP were prepared by spray drying and the 47	
physicochemical characteristics were evaluated. 48	
Results: The nanoparticles were 200 nm in diameter both before loading into and after 49	
redispersion from nCmP. The NP exhibited smooth, spherical morphology and the nCmP were 50	
corrugated spheres about 1 µm in diameter. Both drugs were successfully encapsulated into the 51	
NP and were released in a sustained manner. The NP were successfully loaded into nCmP with 52	
favorable encapsulation efficacy. All materials were stable at manufacturing and storage 53	
conditions and nCmP were in an amorphous state after spray drying. nCmP demonstrated 54	
desirable aerosol dispersion characteristics, allowing them to deposit into the deep lung regions 55	
for effective drug delivery. 56	
Conclusions: The described nCmP have the potential to overcome mucus-limited pulmonary 57	
delivery of antibiotics. 58	
 59	
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 73	
INTRODUCTION 74	
 Cystic fibrosis (CF) is a progressive, incurable, autosomal recessive disease that affects around 75	
70,000 people worldwide (1, 2). It is caused by mutations in the cystic ﬁbrosis transmembrane 76	
conductance regulator (CFTR) gene, which leads to defective or insufficient amounts of 77	
functional CFTR proteins. The dysfunctional proteins result in an absence or decrease of chloride 78	
in secretions, leading to increased sodium and water absorption and airway surface liquid 79	
depletion (3). CF affects various organ systems of patients including the sweat glands, 80	
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reproductive tract, intestine, liver, pancreas, and respiratory tract (4), in which lung disease is the 81	
primary cause of mortality (4, 5). The dysfunction of the respiratory tract results in frequent 82	
pulmonary infections, inﬂammation, bronchiectasis, and eventually respiratory failure, which 83	
causes over 90% of deaths in CF patients (6). Pulmonary infection is one of the primary 84	
complications among patients with CF and these patients tend to develop chronic infections 85	
within a year if no treatment is implemented, which will accelerate the decline in lung function, 86	
resulting in earlier mortality (7, 8).  87	
 Pseudomonas aeruginosa (P. aeruginosa) is regarded as the most prevalent pathogen in CF 88	
patients’ lungs (7, 9). Azithromycin (AZI) is a macrolide antibiotic with a broad gram-negative 89	
antibacterial spectrum and is highly effective against planktonic, actively growing bacteria (10). 90	
AZI has been extensively studied for the treatment of CF-related infections due to its ability to 91	
decrease P. aeruginosa accumulation (10-15) as well as its pharmacokinetic advantages including 92	
high bioavailability, distribution, and extended half-life (13, 14). 93	
 Burkholderia cenocepacia (B. cepacia) infection is also considered to be a lethal threat to CF 94	
patients because it causes severe and persistent lung inflammation and it is resistant to nearly all 95	
available antibiotics (16). Rapamycin (RAP), also known as sirolimus, is an immunosuppressive 96	
macrolide that is the most commonly used chemical to induce autophagy (17). It has been shown 97	
that RAP can markedly decrease B. cepacia infection in vitro by enhancing the clearance of this 98	
bacterium via induced autophagy. RAP has been shown to reduce bacterial burden and decrease 99	
inflammation in the lungs of CF infected mice (16). 100	
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 Acetalated dextran (Ac-Dex) is an acid sensitive, biodegradable, biocompatible polymer that 101	
can be prepared in a one-step reaction by reversibly modifying dextran with acetal groups (18). 102	
This modification reverses the solubility properties of dextran from hydrophilic to hydrophobic, 103	
making it possible to form polymeric particles using standard emulsion or nanoprecipitation 104	
techniques. Drug loaded Ac-Dex nanoparticles exhibit sustained release profile, with the 105	
advantages of extended duration of action, decreased drug use, improved management of therapy, 106	
enhanced compliance and reduced side effects. (19, 20) In comparison to other commonly used 107	
polymers in drug delivery such as poly(lactic-co-glycolic acid) (PLGA) and polyesters, Ac-Dex 108	
offers several advantages. Most notably, the degradation rate of Ac-Dex can be tuned from 109	
minutes to months by modifying the ratio of cyclic and acyclic acetal groups, which have 110	
different rates of hydrolysis. Also, Ac-Dex degrades into dextran, a biocompatible, biodegradable, 111	
FDA-approved by-product, and very low levels of methanol and acetone (20-22). 112	
 Mannitol, an FDA approved, non-toxic, readily degradable sugar alcohol commonly used in 113	
pharmaceutical products, was applied as the excipient of nCmP due to its beneficial properties.(23) 114	
First, mannitol can be rapidly dissolved into an aqueous environment, leading to a burst release of 115	
encapsulated nanoparticles. In addition, mannitol can improve the fluidity of mucus, thus 116	
enhancing the mucus penetration rate of nanoparticles (24). Mannitol has been extensively studied 117	
as a carrier in spray-dried powder aerosols for pulmonary drug administration and the resulting 118	
particles have been shown to exhibit desirable water content, size, and surface morphology for 119	
successful aerosol delivery (25, 26). 120	
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 Pulmonary antibiotic delivery is increasingly recommended as maintenance therapy to prolong 121	
the interval between pulmonary exacerbations and to slow the progression of lung disease of CF 122	
patients due to the capability of these systems to achieve high drug concentrations at the site of 123	
infection and to minimize the risk of systemic toxicity and drug resistance (31-34). Extensive 124	
studies have been devoted to the development of new inhalation devices and advanced drug 125	
delivery formulations for the treatment of CF-related infections (35-38). Despite these advances, 126	
there has only been incremental improvement in the treatment of pulmonary infections. This is 127	
partly due to the presence of mucus in the lung airways that can trap and remove foreign particles. 128	
Also, the abnormally thick and viscous mucus in the respiratory tract of CF patients impairs 129	
efficient mucus penetration and limits the efficacy of antibiotics delivered via inhalation. 130	
Polyethylene glycol (PEG)-coated nanoparticles have been shown to significantly improve the 131	
mucus penetration of various therapeutics encapsulated in NP due to the formulation size, PEG 132	
coating, and protection of active pharmaceutical ingredients (39). Unfortunately, aerosolized 133	
nanoparticles will be exhaled owing to their small size and mass and while aerosolized particles 134	
with aerodynamic diameters of 1-5 µm can deposit into the deep lung region, which limits their 135	
efficacy for targeting the infection site in mucus as aerosol drug delivery vehicles (40, 41).  136	
 To overcome the aforementioned obstacles of pulmonary antibiotic delivery, we developed 137	
nanocomposite microparticles (nCmP) in the form of dry powder aerosols (Figure 1). This system 138	
is comprised of drug-loaded nanoparticles (NP) entrapped in microparticle carriers with the 139	
excipient mannitol to allow for the delivery of mucus-penetrating NP to the lungs. The 140	
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drug-loaded nanoparticles contain azithromycin or rapamycin as model drugs and are coated by a 141	
vitamin E poly(ethylene glycol) (MW 5000) layer, which has shown to improve the stability and 142	
mucus penetration rate of nanoparticles (39). Upon pulmonary administration, the nCmP will 143	
deposit on the mucus in the respiratory tract, dissociate into free NP and mannitol, and allow the 144	
nanoparticles to penetrate the mucus and then release drug to the targeted site at sustained rate. 145	
This nCmP system exhibits features favorable for dry powder-based antibiotic delivery including 146	
targeted delivery, rapid mucus penetration, and controlled drug release. The goal of the described 147	
research was the initial development and physicochemical characterization of the nCmP systems 148	
via particle engineering. 149	
 150	
MATERIALS AND METHODS 151	
Materials 152	
 Dextran from Leuconostoc mesenteroides (9000 - 11000 MW), pyridinium 153	
p-toluenesulfonate (PPTS, 98%), poly(ethylene glycol) methyl ether (mPEG, Mn 5000), D-α154	
-tocopherol succinate (vitamin E succinate, 1210 IU/g), N,N'-dicyclohexyl- carbodiimde (DCC, 155	
99%), 4-(dimethylamino) pyridine (DMAP, ≥ 99%), potassium phosphate dibasic, potassium 156	
phosphate monobasic, D-mannitol (≥ 98%), 2-methoxypropene (2-MOP, 97%), triethylamine 157	
(TEA, ≥ 99%), anhydrous dimethyl sulfoxide (DMSO, ≥ 99.9%), deuterium chloride (DCl, 35 158	
weight % in D2O, 99 atom % D), deuterated chloroform (CDCl3, 100%, 99.96 atom % D), 159	
TWEEN® 80，methanol (HPLC grade, ≥ 99.9%), and acetonitrile (HPLC grade, ≥ 99.9%) 160	
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were obtained from Sigma–Aldrich (St. Louis, MO). Ethanol (anhydrous, ASC/USP grade) was 161	
obtained from Pharmco-AAPER (Brookfield, CT). Deuterium oxide (D2O, 99.8% atom D) was 162	
obtained from Acros Organics (Geel, Belgium). Phosphate buffered saline (PBS) was obtained 163	
from Fisher Scientific. Hydranal® KF reagent was obtained from Fluka Analytical. Rapamycin 164	
was obtained from LC Laboratories (Woburn, MA). Azithromycin was obtained from AstaTech 165	
Inc. (Bristol, PA). 166	
 167	
Synthesis of Acetalated Dextran (Ac-Dex) 168	
 Ac-Dex was synthesized as described previously (22) with minor modifications. Briefly, 1 g 169	
of lyophilized dextran and 25 mg of PPTS were dissolved in 10 mL anhydrous DMSO. The 170	
resulting solution was reacted with 5 mL of 2-MOP under nitrogen gas for 5 minutes and was 171	
quenched with 1 mL of TEA. The reaction mixture was then precipitated in basic water (water 172	
and TEA, pH 9), vacuum filtered, and lyophilized (−50 °C, 0.023 mbar) for 24 hours to yield a 173	
solid product.  174	
 175	
Synthesis of Vitamin E Poly(ethylene glycol) (VP5k) 176	
 VP5k was prepared with some modifications to a previously described method (42). 0.65 g 177	
of vitamin E succinate and 7.334 g of mPEG were dissolved in 20 mL of DCM. 0.278 g of DCC 178	
and 15 mg of DMAP were added to the solution. The reaction mixture was stirred at room 179	
temperature overnight, vacuum filtered (0.45 µm), and concentrated under reduced pressure via a 180	
rotor evaporator (IKA-RV, Wilmington, NC) to obtain a crude product. The resulting crude 181	
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product was dissolved at 5% (w/v) in DI water and centrifuged at 12000 rpm for 30 minutes. The 182	
filtrate was vacuum filtered (0.22 µm) and lyophilized (−50 °C, 0.023 mbar) for 72 hours to yield 183	
the final product.  184	
 185	
NMR Analysis of Ac-DEX and VP5k 186	
 The cyclic-to-acyclic (CAC) ratio of acetal coverage and degrees of total acetal coverage per 187	
100 glucose molecules was confirmed by 1H NMR spectroscopy (Bruker 300 MHz NMR, MA). 188	
10 mg of Ac-Dex was added to 700 µL of D2O and was hydrolyzed with 30 µL of DCl prior to 189	
analysis. The hydrolysis of one cyclic acetal group produces one acetone whereas one acyclic 190	
acetal produces one acetone and one methanol. Consequently, from the normalized integrations 191	
of peaks related to acetone, methanol, and the carbon ring of dextran, the CAC ratio of acetal 192	
coverage and degrees of total acetal coverage per 100 glucoses were determined.  193	
 Conjugation of mPEG to Vitamin E succinate was also confirmed by NMR spectroscopy. 20 194	
mg of VP5k was dissolved in 600 µL of CDCl3. The resulting solution was analyzed by 2D 195	
1H-13C HMBC-GP NMR spectroscopy. Shift of the signal at 2.8 ppm and 178.8 ppm related to 196	
the -COOH group of vitamin E succinate and 2.7 ppm and 172.2 ppm related to the ester group 197	
indicated conjugation of mPEG to vitamin E succinate for the successful formation of VP5k.  198	
 199	
Preparation of Drug-loaded Nanoparticles 200	
 Azithromycin (AZI)-loaded nanoparticles and rapamycin (RAP)-loaded nanoparticles were 201	
prepared via nanoprecipitation. 40 mg of Ac-Dex and 12 mg of AZI or 4 mg of RAP were 202	
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dissolved in 1 mL of ethanol and injected into 40 mL of 1.5 % (w/v) VP5k solution. The 203	
resulting suspension was stirred for 3 hours for removal of ethanol and hardening of the particles 204	
and the final solution was centrifuged at 12000 rpm for 20 minutes to collect the NP. The NP 205	
were washed once with basic water and lyophilized for 24 hours to give the final AZI-NP and 206	
RAP-NP systems.  207	
 208	
Preparation of Nanocomposite Microparticles (nCmP)   209	
 nCmP were prepared via the spray drying of a AZI NP or RAP NP suspensions and mannitol 210	
in an aqueous solution using a Büchi B-290 spray dryer (Büchi Labortechnik, AG, Switzerland) 211	
in open mode. The spray drying conditions were as follows: 1:1 (w:w) ratio of NP to mannitol in 212	
DI water; feed solution concentration of 1% (w/v); 1.4 mm nozzle diameter; atomization gas 213	
flow rate of 414 L/h (UHP dry nitrogen); aspiration rate of 28 m3/h, inlet temperature of 50 °C; 214	
pump rate of 0.6 mL/min; and nozzle cleaner rate of 4. The resulting nCmP were separated in a 215	
high-performance cyclone, collected in a sample collector, and stored in amber glass vials in 216	
desiccators at −20°C. 217	
 218	
Powder X-Ray Diffraction (PXRD) 219	
 Crystalline states of the nCmP were examined by PXRD using a Rigaku Multiflex X-ray 220	
diffractometer (The Woodlands, TX) with a Cu Kα radiation source (40 kV, 44 mA). The 221	
samples were placed on a horizontal quartz glass sample holder (3 mm). The scan range was 5 – 222	
65° in 2Θ with a step width of 0.02 and scan rate of 2°/min. 223	
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 224	
Differential Scanning Calorimetry (DSC) 225	
 The thermal phase transitions of the nCmP were determined by DSC using a TA Q200 DSC 226	
system (TA Instruments, New Castle, DE, USA) equipped with an automated 227	
computer-controlled RSC-90 cooling accessory. 1 - 3 mg of sample was weighed into Tzero™ 228	
alodined aluminum pans that were hermetically sealed. The sealed pans were placed into the 229	
DSC furnace along with an empty sealed reference pan. The heating range was 0 – 250 °C at a 230	
heating rate of 10 °C/min. 231	
 232	
Scanning Electron Microscopy (SEM) 233	
 The shape and surface morphology of the NP and nCmP were evaluated by SEM using a 234	
Hitachi S-4300 microscope (Tokyo, Japan). nCmP samples were placed on aluminum SEM stubs 235	
(TedPella, Inc., Redding, CA, USA) with double-sided adhesive carbon tabs. Nanoparticles were 236	
dispersed in basic water (pH = 9, 10 mg/mL) and this suspension was dropped onto aluminum 237	
SEM stubs and then dried at room temperature. Both the NP and nCmP samples were coated 238	
with a thin film of a gold/palladium alloy using an Emscope SC400 sputter coating system at 20 239	
µA for 75 seconds under argon gas. Images were captured at 5 kV. 240	
 241	
Particle Size, Size Distribution and Zeta Potential Analysis 242	
 The size, size distribution, and zeta potential of the NP systems were measured by dynamic 243	
light scattering (DLS) using a Malvern Nano Zetasizer (Malvern Instruments, Worcestershire, 244	
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UK). The NP were dispersed in basic water (pH = 9, 0.3 mg/mL). All experiments were 245	
performed in triplicate with a scattering angle of 173° at 25 °C. The mean size and standard 246	
deviation of the nCmP were measured digitally from SEM images using ImageJ software (Systat, 247	
San Jose, CA, USA). Representative micrographs (5k magnification) for each sample were 248	
analyzed by measuring the diameter of at least 100 particles. 249	
 250	
Karl Fischer (KF) Titration 251	
 The water content of the nCmP was quantified by Karl Fischer (KF) titration using a 737 KF 252	
coulometer (Metrohm, Riverview, FL). Approximately 10 mg of powder was dissolved in 253	
anhydrous methanol. The resulting solution was injected into the KF reaction cell filled with 254	
Hydranal® KF reagent and then the amount of water was analyzed. Pure solvent was also 255	
injected for use as a background sample.  256	
 257	
Aerosol Dispersion Analysis  258	
 In vitro aerosol dispersion performance of the nCmP was evaluated using a Next Generation 259	
Impactor™ (NGI™, MSP Corporation, Shoreview, MN) equipped with a stainless steel 260	
induction port (USP throat adaptor) attachment and stainless steel NGI™ gravimetric insert cups. 261	
The NGI™ was coupled with a Copley TPK 2000 critical flow controller, which was connected 262	
to a Copley HCP5 vacuum pump (Copley Scientific, United Kingdom). The airflow rate (Q) was 263	
measured and adjusted to 60 L/min in order to model the flow rate in a healthy adult lung before 264	
each experiment. Glass fiber filters (55 mm, Type A/E, Pall Life Sciences, PA) were placed in 265	
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the gravimetric insert cups for stages 1 through 7 to minimize bounce or re-entrapment (43) and 266	
these filters were weighed before and after the experiment to determine the particle mass 267	
deposited on each stage. Approximately 10 mg of powder was loaded into a hydroxypropyl 268	
methylcellulose (HPMC, size 3, Quali-V®, Qualicaps® Inc., Whitsett, NC, USA) capsule and 269	
the capsule was placed into a human dry powder inhaler device (HandiHaler, Boehringer 270	
Ingelheim Pharmaceuticals, CT) attached to a customized rubber mouthpiece connected to the 271	
NGI™. Three HPMC capsules were loaded and released in each measurement and experiments 272	
were performed in triplicate. The NGI™ was run with a delay time of 10 s and running time of 273	
10 s. For Q = 60 L/min, the effective cutoff diameters for each stage of the impactor were given 274	
from the manufacturer as: stage 1 (8.06 µm); stage 2 (4.46 µm); stage 3 (2.82 µm); stage 4 (1.66 275	
µm); stage 5 (0.94 µm); stage 6 (0.55 µm); and stage 7 (0.34 µm). The fine particle dose (FPD), 276	
fine particle fraction (FPF), respirable fraction (RF), and emitted dose (ED) were calculated as 277	
follows: 278	
 279	
 
Fine particles dose (FPD) = mass of particles on Stages 2 through 7
Fine particles fraction (FPF) = fine particles dose
initial particle mass loaded into capsules
 ×  100%
Respirable fraction (RF) = mass of particles on Stages 2 through 7
total particle mass on all stages
 ×  100%
Emitted dose (ED) = initial mass in capsules - final mass remaining in capsules
initial mass in capsules
 ×  100%
 280	
  281	
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 The mass median aerodynamic diameter (MMAD) and geometric standard deviation (GSD) 282	
for the particles were determined using a Mathematica® program written by Dr. Warren Finlay 283	
(43, 44). 284	
 285	
Analysis of Nanoparticle Drug Loading and Nanoparticle Loading in nCmP 286	
 Drug loading and encapsulation efficacy of AZI and RAP NP and nCmP were determined 287	
using high performance liquid chromatograph (HPLC) (Hitachi Elite LaChrom, Japan). 288	
Detection of AZI was performed using the following conditions: C18, 5 µm × 150 mm × 4.6 mm 289	
column (XTerra™, Waters); 1.5 mL/min pump rate; 6 minute retention time; mobile phase of 70% 290	
methanol and 30% PBS (0.03 M, pH = 7.4); absorbance of 215 nm; and ambient temperature. 291	
Detection of RAP was performed using following conditions: C18, 5 µm × 150 mm × 4.6 mm 292	
column (Supelco, Sigma-Aldrich, St. Louis, MO); 1 mL/min pump rate; 6 minute retention time; 293	
mobile phase of 65% acetonitrile and 35% DI water; absorbance of 278 nm; and temperature of 294	
50°C. Drug-loaded NP and nCmP were fully dissolved in their respective mobile phases. The 295	
experimental drug concentration in each sample was quantified by comparison with a standard 296	
curve of drug in its mobile phase. The drug loading of NP, drug loading of nCmP, NP loading in 297	
nCmP, drug encapsulation efficiency of NP, and NP encapsulation efficacy in nCmP were 298	
determined by the following equations: 299	
 300	
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Drug loading  = mass of drug loaded in nanoparticles
mass of particles
 ×  100%
Drug encapsulation efficacy (EE) = mass of drug loaded in nanoparticles
initial mass of drug in particle formulation
 ×  100%
Nanoparticles loading  = mass of NPs loaded in nCmPs
mass of nCmPs
 ×  100%
NP loading efficacy  = mass of NPs loaded in nCmPs
initial mass of NPs in nCmPs formulation
 ×  100%
 301	
 302	
In Vitro Drug Release from Nanoparticles 303	
 The in vitro release profiles of AZI or RAP from nanoparticles was determined via a release 304	
study of NP suspended (1 mg/mL) in modified phosphate buffer (0.1 M, pH = 7.4) with 0.2% 305	
(w/v) of Tween® 80. The suspension was incubated at 37 °C and 100 rpm. At various time 306	
points (0 to 48 h), NP samples were centrifuged at 14000 rpm for 5 minutes at 4 °C to isolate the 307	
NP. 200 µL of supernatant was withdrawn and replaced by the same amount of fresh modified 308	
PBS in each sample. The withdrawn solutions were analyzed for drug content via HPLC using 309	
the same methods described in the previous section. 310	
 311	
Statistical analysis 312	
    All measurements were performed in at least triplicate. Values are given in the form of 313	
means ± SD. The statistical significance of the results was determined using t-Test. A p-value of 314	
<0.05 was considered statistically significant. 315	
 316	
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RESULTS AND DISCUSSION 317	
NMR Analysis of Ac-Dex and VP5k 318	
 Successful synthesis of Ac-Dex and VP5k was confirmed by NMR (Figure S1 in 319	
Supplemental Information). Ac-Dex exhibited 68.7% cyclic acetal coverage (CAC) and 79.1% 320	
total acetal coverage (conversion of -OH groups). A yield of approximately 95% was obtained 321	
for this Ac-Dex. An increase in CAC is known to slow drug release due to slower 322	
degradation.(21, 22) A high total acetal coverage (higher than 75% according to our research) is 323	
required to stabilize the VP5k coating of nanoparticles, which ensures small particles size and 324	
narrow size distribution. The signals for ester groups were detected via NMR, indicating 325	
successful conjugation of mPEG to vitamin E succinate for the successful formation of VP5k 326	
(45). The yield of VP5k was approximately 30%. 327	
 328	
Characterization of Nanoparticles 329	
 The azithromycin-loaded nanoparticles (AZI-NP), shown in Figure 2A, appear as uniform 330	
spheres with smooth surface morphology. NP size, size distribution, and zeta potential are shown 331	
in Table 1. The resulting sizes of the NP analyzed via DLS (approximately 200 nm) were larger 332	
than those observed from SEM micrographs and ImageJ analysis (approximately 100 nm) due to 333	
shrinking of the particles during freeze-drying from the collapse of hydrated PEGylated chains 334	
(46). Both drug-loaded NP systems exhibited desirable size (less than 200 nm) with narrow size 335	
distribution to allow for potential mucus penetration. The relative surface charge of the NP 336	
systems were nearly neutral, confirming PEG coverage on their surfaces (45). Similar results 337	
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were obtained for drug-loaded and blank nanoparticles with respect to their size, size distribution, 338	
and surface charge, indicating that drug encapsulation did not affect the formation of the NP.  339	
 Both AZI and RAP were successfully encapsulated into the described NP systems. 13.0 % of 340	
initial AZI and 25.8 % of initial RAP were effectively entrapped within the NP prepared using 341	
nanoprecipitation of Ac-Dex and drugs in VP5k solution. The low encapsulation of the drugs 342	
may be due to the improved solubility of the drugs in the spinning solution by VP5K micelles. 343	
RAP-NP exhibited a higher encapsulation efficacy as a result of the lower solubility of RAP than 344	
AZI in the aqueous spinning solution.    345	
 Results of the in vitro release of AZI-NP and RAP-NP at physiological pH and temperature 346	
are reported in Figure 3 as the percentage of drug released over time. Both NP systems 347	
displayed sustained release for approximately 12 hours, which matched the degradation profile 348	
of other Ac-Dex particle systems (43). Based on previous research, Ac-Dex made of 10kDa 349	
dextran and reacted for 5 minutes showed a maximum of degradation at 6 hours and negligible 350	
degradation after that (47). A possible explanation of the release profiles could be that the first 351	
release stage corresponds to Ac-Dex degradation as well as nanoparticle dissociation, whereas 352	
after 6 hours the rate of drug release is controlled by drugs passively diffuse out of the 353	
dissociated matrix of nanoparticles following the partial degradation of Ac-Dex. 354	
 355	
 356	
Manufacturing of nCmP 357	
With respect to nCmP manufacturing, the outlet temperatures of AZI- and RAP-nCmP were 358	
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30 - 31 °C and 30 - 33 °C, respectively, while the yields were 62.4% and 60.6%, respectively. 359	
 360	
nCmP Morphology, Sizing, and Size Distribution 361	
 As seen in the SEM images, the AZI-nCmP were mostly spherical with a corrugated surface 362	
(Figure 2B) and encapsulated nanoparticles were visible on the surface of the nCmP as seen in 363	
Figure 2C. Both RAP-NP and RAP-nCmP exhibited the same morphology as the AZI loaded 364	
systems (data not shown). The number average geometric diameters were 1.03 ± 0.46 and 1.12 ± 365	
0.43 µm for AZI-nCmP and RAP-nCmP, respectively, as determined by ImageJ analysis. Both 366	
nCmP systems exhibited similar morphology, geometric size, and size distribution due to the 367	
similarities in spray drying conditions. 368	
 369	
Karl Fisher (KF) Titration 370	
 The residual water contents of AZI-nCmP and RAP-nCmP were approximately 6% (Table 371	
2). This is within the range of other nCmP in our group (results not published) and that of 372	
previously reported inhalable dry powder formulations prepared by other groups (25, 48-51). 373	
Water in inhalable powders can significantly reduce their dispersion properties during 374	
aerosolization due to the interparticulate capillary forces acting at the solid–solid interface 375	
between particles (52) and also have a negative effect on the stability of the powders (50). 376	
Correspondingly, low water content in the powder is highly favorable for efficient dry powder 377	
aerosolization and effective particle delivery (52, 53).  378	
 379	
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Differential Scanning Calorimetry (DSC) 380	
 Figure 4 shows DSC thermograms of the raw materials used in particle preparation and the 381	
final drug-loaded nCmP. Raw Ac-Dex, AZI, RAP, and mannitol displayed endothermic main 382	
phase transition peaks (Tm) near 170, 140, 180, and 170 °C respectively, which are in accordance 383	
with previously reported values (54-56). The drug-loaded nCmP systems exhibited similar 384	
thermal behaviors with a main phase transition peak near 165 °C corresponding to the melting of 385	
Ac-Dex and mannitol. This melting point was lower than those of raw Ac-Dex and mannitol, 386	
indicating an increase in the amorphous state of these raw materials in nCmP. No glass transition 387	
or other phase transitions were present under 120 °C, which indicated that all the materials will 388	
be stable during manufacturing and storage.  389	
 390	
Powder X-ray Diffraction (PXRD) 391	
 X-ray diffraction diffractograms of the raw materials and drug-loaded nCmP are shown in 392	
Figure 5. Strong peaks were present for raw AZI, RAP, and mannitol powders. These strong 393	
peaks indicate that the raw materials are in their crystalline forms prior to spray drying, which is 394	
in accordance with previous research (54-56). No strong peaks were present for raw Ac-Dex, 395	
indicating that it is non-crystalline. This is quite different from commercialized polymers such as 396	
PLGA, which exhibits strong XRD characterization peaks (54-57). The absence of diffraction 397	
peaks in Ac-Dex is likely because the Ac-Dex is collected by rapid precipitation in water. XRD 398	
patterns of AZI-nCmP and RAP-nCmP showed the absence of any diffraction peaks, suggesting 399	
amorphization of raw AZI and RAP in the particle matrix. Also, the peaks characterizing 400	
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mannitol were significantly reduced, indicating that mannitol is primarily in an amorphous state 401	
in the nCmP. The results obtained from the XRD diffractograms confirmed those from DSC 402	
thermograms, where raw AZI, RAP, and mannitol were converted into amorphous form in the 403	
nCmP manufacturing process. 404	
 405	
Drug and Nanoparticles Loading in nCmP 406	
 HPLC was used to determine the amount of drug loading in nCmP, which can be used to 407	
calculate the resulting nanoparticles loading and nanoparticle encapsulation efficacy in nCmP. 408	
These results are shown in Table 2. Both AZI- and RAP-nCmP exhibited desirable drug loading, 409	
high nanoparticle loading, and nanoparticle encapsulation efficacy. In addition, standard 410	
deviations of these three values were very low, which indicated reproducible drug loading of the 411	
nCmP can be achieved.  412	
 413	
Nanoparticle Redispersion from nCmP 414	
 The properties of NP redispersed from nCmP were evaluated using DLS (Table S1 in 415	
Supplementary Material). The size and size distribution of the NP increased after redispersion, 416	
which is likely a result of agglomeration that occurred during spray drying. The NP surface 417	
charges remained neutral due to the presence of PEG on the surface of the NP. These parameters 418	
were all within the desirable ranges for effective mucus penetration.   419	
 420	
In vitro Aerosol Performance of nCmP 421	
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 In vitro aerosol dispersion performance properties (Figure 6 and Table 2) of the nCmP were 422	
evaluated using a Next Generation Impactor™ coupled with a human DPI device. The results 423	
indicated that the formulated nCmP are favorable for efficient dry powder aerosolization and 424	
effective targeted delivery. The MMAD values of AZI-nCmP and RAP-nCmP were 3.93 ± 0.09 425	
and 3.86 ± 0.07 µm, while the GSD values were 1.73 ± 0.06 and 1.78 ± 0.06 µm, respectively. 426	
The MMAD values were within the range of 1 - 5 µm, which is required for predominant 427	
deposition of nCmP into the deep lung region where infection persists (49). The GSD values 428	
were within those previously reported and the RF, FPF, and ED values were all higher (43, 49, 429	
58). Assuming that nCmP drug loading is homogenous, fine particle doses in terms of drug mass 430	
of AZI-nCmP and RAP-nCmP are 110.42 ± 0.22 µg and 100.97 ± 9.19 µg. There is no 431	
research on the therapeutic level of rapamycin for the treatment of CF-related infection. Oral 432	
delivery of azithromycin requires 500 mg/week to 1500 mg/ week, but the bioavailability is 433	
limited.(13) The nCmP system is expected to achieve therapeutic effect using a low drug amount 434	
by improving the delivery efficacy. 8.1% and 9.4% of AZI-nCmP and RAP-nCmP deposited on 435	
stages 5 - 7, respectively, and are predicted to deposit in the deep lung alveolar region due to 436	
diffusion mechanisms (59) of deposition, while approximate 84% of both the nCmP deposited on 437	
stages 2 - 4, and are predicted to deposit predominantly in the deep lung regions by 438	
sedimentation due to gravitational settling (60-62). Overall, the nCmP exhibited desirable 439	
aerosol dispersion characteristics allowing them to deposit in deep lung regions for drug 440	
delivery. 441	
    442	
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Summary 443	
Both nCmP systems exhibited similar morphology, geometric size, size distribution, water 444	
content, drug loading, nanoparticles loading, and nanoparticle encapsulation efficacy as well as 445	
outlet temperature and yield due to the fact that they were prepared with nanoparticles with the 446	
same spray drying conditions. 447	
 448	
CONCLUSIONS 449	
 Both azithromycin and rapamycin were successfully encapsulated in Ac-Dex nanoparticles 450	
and can be released in a sustained rate. The drug-loaded nanoparticles were smooth spheres 200 451	
nm in diameter with narrow size distribution and slightly negative surface charge, which is 452	
desirable for mucus penetration. Most nanoparticles maintained these properties during the 453	
nCmP manufacturing process as shown in redispersion testing. The nCmP systems were 454	
corrugated spheres of 1 µm with observable nanoparticles present on their surfaces. The water 455	
content of the nCmP systems was relatively low, which can enable efficient dry powder 456	
aerosolization and particle delivery. None of the raw materials underwent degradation during 457	
nCmP manufacturing, indicating the stability of the therapeutics during formation. No crystalline 458	
structures of AZI and RAP were observed in the nCmP, which confirmed that both drugs in the 459	
nCmP were in their amorphous form. In vitro aerosol performance testing demonstrated 460	
desirable aerosol dispersion characteristics of nCmP, allowing them to deposit in deep lung 461	
regions for drug delivery. 462	
 This nCmP system sheds a light on dry powder-based antibiotic delivery due to its novel 463	
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features including targeted pulmonary delivery, rapid mucus penetration potential, and controlled 464	
drug release. It can be applied as a promising alternative of the traditional antibiotic treatment by 465	
providing effective delivery of therapeutics, more convenient administration, more flexible 466	
storage conditions, and lower risk of contamination in the device. 467	
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 681	
 682	
TABLES AND FIGURES 683	
 684	
Table 1. Size (as measured by dynamic light scattering), polydispersity index (PDI), zeta 685	
potential (ζ), drug loading, and encapsulation efficiency (EE) of nanoparticles (mean ± standard 686	
deviation, n = 3). 687	
NP 
System 
Diameter 
(nm) PDI 
ζ Potential 
(mV) 
Drug Loading (mg 
drug/100mg NP) EE (%) 
AZI-NP 204.7 ± 0.4 0.11 ± 0.01 -4.62 ± 0.19 3.89 ± 2.67 13.0 ± 0.9 
RAP-NP 189.1 ± 1.1 0.16 ± 0.02 -2.26 ± 0.14 2.58 ± 0.04 25.8 ± 0.4 
Blank 211.4 ± 3.2 0.18 ± 0.03 -6.13 ± 0.62 n/a n/a 
 688	
 689	
Table 2. Size (as measured by SEM imaging and ImageJ analysis), water content, drug loading, 690	
nanoparticle (NP) loading in nanocomposite microparticles (nCmP), and NP loading efficacy in 691	
nCmP (mean ± standard deviation, n = 3). 692	
nCmP 
System 
Diameter 
(µm) 
Water 
Content (%) 
Drug Loading 
(mg drug/100 mg 
nCmP) 
NP 
Loading 
(%) 
NP Loading 
Efficacy (%) 
AZI-nCmP 1.03 ± 0.46 5.7 ± 1.25 0.77 ± 0.08 20.47 ± 1.80 40.94 ± 3.60 
RAP-nCmP 1.12 ± 0.43 6.1 ± 1.05 0.56 ± 0.02 20.14 ± 0.68 44.28 ± 1.34 
 693	
 694	
Table 3. In vitro aerosol dispersion performance properties including mass median aerodynamic 695	
diameter (MMAD), geometric standard deviation (GSD), fine particle dose (FPD), fine particle 696	
fraction (FPF), respirable fraction (RF), and emitted dose (ED) for nCmP (mean ± standard 697	
deviation, n = 3). 698	
 699	
nCmP 
system 
MMAD 
(µm)  
GSD (µm)  FPD (mg) FPF 
(%) 
RF 
(%) 
ED (%) 
AZI-nCmP 3.93 ± 0.09 1.73 ± 0.06 19.63 ± 0.59 93.9 ± 
1.3 
79.7 ± 
0.8 
98.9 ± 0.4 
RAP-nCmP 3.86 ± 0.07 1.78 ± 0.06 20.90 ± 0.62 92.5 ± 
1.7 
73.6 ± 
2.1 
99.7 ± 0.3 
 700	
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 701	
Figure 1. Schematic of an aerosol nanoparticle microparticle (nCmP) system interacting with the 702	
pulmonary mucosa. Once the nCmP impact the surface of the mucus coating the pulmonary 703	
epithelium they immediately degrade to release nanoparticles. 704	
 705	
 706	
 707	
Figure 2. Representative SEM micrographs of azithromycin (AZI) nanoparticles (NP) and 708	
nanocomposite microparticles (nCmP) including: (A) AZI-NP, (B) AZI-nCmP, (C) 709	
Representative zoomed in image of AZI-nCmP. 710	
 711	
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 712	
Figure 3. In vitro drug release profiles for azithromycin (AZI) and rapamycin (RAP) 713	
nanoparticle systems. 714	
 715	
 716	
 717	
Figure 4. Differential scanning calorimetry (DSC) thermograms of raw azithromycin (AZI), raw 718	
rapamycin (RAP), raw acetalated dextran (Ac-Dex), raw mannitol, AZI-nCmP, and RAP-nCmP. 719	
	 32 
  720	
 721	
Figure 5. Powder X-ray (PXRD) diffractograms of raw azithromycin (AZI), raw rapamycin 722	
(RAP), raw acetalated dextran (Ac-Dex), raw mannitol, AZI-nCmP, and RAP-nCmP. 723	
 724	
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 725	
 726	
Figure 6. Aerosol dispersion performance as % deposited on each stage of the Next Generation 727	
Impactor™ (NGI™) for AZI- and RAP-nCmP. 728	
 729	
 730	
 731	
 732	
 733	
 734	
 735	
 736	
 737	
 738	
 739	
 740	
 741	
 742	
 743	
 744	
 745	
 746	
 747	
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SUPPLEMENTARY MATERIAL 748	
Table S1. Characterization of nanoparticles after redispersion from nanocomposite 749	
microparticles in PBS including the size, polydispersity index (PDI), and zeta (ζ) potential. 750	
 751	
System Diameter (nm) PDI ζ Potential (mV) 
AZI-NP 327.6 ± 3.7 0.32 ± 0.02 -7.66 ± 0.68 
RAP-NP 348.2 ± 11.6 0.43 ± 0.01 -5.99 ± 0.07 
Blank-NP 270.8 ± 10.8 0.26 ± 0.04 -3.98 ± 0.67 
 752	
 753	
 754	
 755	
 756	
 757	
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 758	
Figure S1. NMR spectra where (top) indicates entire spectra and (bottom) is an enlarged portion. 759	
